The Pharmaceutical Merger That Could Rewrite Industry Rules A potential £300 billion merger between AstraZeneca and Bristol Myers Squibb has sent shockwaves through the pharmaceutical industry, sparking both excitement and concern among investors and analysts.
If reports of ongoing talks between the two companies are true, this deal would create one of the largest drug giants in history and have significant implications for the sector's future.
AstraZeneca's pursuit of a major merger is consistent with its ambitious plans to expand its presence in the US market under CEO Pascal Soriot.